As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Regentis Biomaterials Ltd. The largest reported stake is Dr. Ehud Geller's, at 23.2%. 2 filings are on record since February 17, 2026 (Schedule 13G, February 17, 2026).
Sell to companies like Regentis Biomaterials Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Regentis Biomaterials Ltd. has 2 Schedule 13D or 13G filings on record since 2026-02-17. 2 holders' latest filing reports 5% or more of common shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 23.2% | 1,332,867 | SCHEDULE 13G, 2026-02-17 | 2025-12-31 | |
| Rosalind Advisors, Inc. | 9.9% | 1,428,570 | SCHEDULE 13G, 2026-08-13 | 2026-06-30 |
Holding shares or following this stake? See who's behind Regentis Biomaterials Ltd. and the warning signs.
Free to see. No signup.
Keep reading
More on Regentis Biomaterials Ltd. and the records around it.
Regentis Biomaterials Ltd. elsewhere on the record
- IPO filing Jul 2026
- Form D filing Jun 2026
- Who owns it
Companies that share a holder
- Rosalind Advisors, Inc. also filed stake reports on 11 other companies: DELCATH SYSTEMS, INC. (Oct 2026), FEMASYS INC (Aug 2026), FENNEC PHARMACEUTICALS INC. (Aug 2026)
Watch Regentis Biomaterials Ltd.
Get an email when Regentis Biomaterials Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Regentis Biomaterials Ltd.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Regentis Biomaterials Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Regentis Biomaterials Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | 0 | 1,428,570 | 0 | 1,428,570 | SCHEDULE 13G, 2026-08-13 |
| Salamon Steven A J | 0 | 1,428,570 | 0 | 1,428,570 | SCHEDULE 13G, 2026-08-13 |
| Aharon Gil | 0 | 1,428,570 | 0 | 1,428,570 | SCHEDULE 13G, 2026-08-13 |
| Rosalind Master Fund L.P. | 0 | 1,428,570 | 0 | 1,428,570 | SCHEDULE 13G, 2026-08-13 |
The latest filing identifies Regentis Biomaterials Ltd. by CUSIP 001219096 and gives its principal executive office as 12 HA'ILAN STREET, NORTHERN INDUSTRIAL, ZONE, P.O. BOX 260, OR AKIVA (SCHEDULE 13G, 2026-08-13).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-17 | Dr. Ehud Geller | 23.2% | SCHEDULE 13G |
| 2026-08-13 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G |
Questions about who owns Regentis Biomaterials Ltd.
Who owns Regentis Biomaterials Ltd.?
On this page, 2 holders' latest ownership filings report 5% or more of Regentis Biomaterials Ltd.: Dr. Ehud Geller (23.2%, Schedule 13G, filed 2026-02-17) and Rosalind Advisors, Inc. (9.9%, Schedule 13G, filed 2026-08-13).
Who are the largest shareholders of Regentis Biomaterials Ltd.?
By the share each holder's latest filing reports, the largest holders of Regentis Biomaterials Ltd. on this page are Dr. Ehud Geller (23.2%) and Rosalind Advisors, Inc. (9.9%).
When did Dr. Ehud Geller buy into Regentis Biomaterials Ltd.?
The filings give report dates, not purchase dates. The earliest filing from Dr. Ehud Geller on this page is the Schedule 13G, filed 2026-02-17, reporting 23.2%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Regentis Biomaterials Ltd.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 8, 2026 | IPO filing, Form F-1 | — | IPO filings | Source |
| June 25, 2026 | Form D, private offering | $6.50M sold | Form D page | Source |
| June 15, 2026 | IPO filing, Form RW | — | IPO filings | Source |
| June 9, 2026 | IPO filing, Form F-1/A | — | IPO filings | Source |
| May 1, 2026 | IPO filing, Form F-1 | — | IPO filings | Source |
| October 24, 2025 | IPO filing, Form F-1/A | $10 to $12 a share | IPO filings | Source |
| September 30, 2025 | IPO filing, Form F-1/A | $10 to $12 a share | IPO filings | Source |
| September 9, 2025 | IPO filing, Form F-1/A | — | IPO filings | Source |
| July 7, 2025 | IPO filing, Form F-1/A | $10 to $12 a share | IPO filings | Source |
| May 19, 2025 | IPO filing, Form F-1/A | $10 to $12 a share | IPO filings | Source |
| May 5, 2025 | IPO filing, Form F-1/A | $10 to $12 a share | IPO filings | Source |
| March 11, 2025 | IPO filing, Form F-1 | $10 to $12 a share | IPO filings | Source |
The newest 12 of 13 records.
Tools for this story
Each opens in a new tab, filled in for Regentis Biomaterials Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.